Big R&D Investment Trend as Mid-Cap Biotechs Push to Get Drugs to Market

Big R&D Investment Trend as Mid-Cap Biotechs Push to Get Drugs to Market

Biotech firms eager to push drug candidates through clinical trials prompted an overall increase in R&D expenditure of 20% in just a year, states research and consulting firm GlobalData.

GlobalData's new report*, which compares the competitive position of 15 innovative mid-cap biotech companies** on 20 financial metrics, states that the peer group R&D spend for Q3 2012 reached US$746.8m, climbing from US$621.1m in Q3 2011.

"Oncology is the main focus of biotech R&D activities," says Adam Dion, GlobalData's Analyst covering Healthcare Industry Dynamics, "which is driving peer group R&D expenses higher."
Regeneron was the firm with the highest R&D expenditure for Q3 2012, with an outlay of US$158m. According to the report, Regeneron's R&D spend has increased steadily each quarter since Q3 2011, when the total stood at US$128m.

"Biotech companies are becoming increasingly more successful at developing innovative therapies," says Dion. "However, our research has found that the high-cost of bringing these therapies to market continues to erode corporate profitability."

In terms of percentages, ViroPharma displayed the biggest year-to-year drop in R&D expenditure. The company's R&D spending plummeted 28% year-to-year, from US$22.9m in Q3 2011 to US$16.5m in Q3 2012.The decrease in ViroPharma's R&D spend was caused by the Food and Drug Administration's suspension of the company's clinical trials of its flagship product Cinryze due to safety concerns.

"The FDA put a hold on two of the company's Phase II clinical studies when trials revealed elevated antibody levels detected in the treatment arm of the study," explains Dion. "These concerns have since been addressed and, with FDA approval, the firm resumed the trials in September of last year."

As defined by a proprietary ratings system based on a number of financial metrics including revenue, sales growth and cost containment, GlobalData identified Regeneron as the peer group benchmark leader in the third quarter, overtaking the Q2 2012 number one, Alexion.
 

** Acorda, Alexion, Alkermes, BioMarin, Cubist, Exelixis, Incyte, Jazz, Momenta, Nektar, Onyx, Regeneron, Seattle, United Therapeutics, and ViroPharma.

-ENDS-

NOTES TO EDITORS

*PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs

This report is part of GlobalData's PharmaLeaders report series. This report applies GlobalData's proprietary ranking methodology to compare the competitive position of 15 innovative biotech companies on 20 financial metrics. The performance of these companies are analyzed on financial performance, cost-containment, capital structure and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders. Lastly, this report provides GlobalData's viewpoint on each company's future revenue outlook, and competitive position within the biotech space.

ABOUT GLOBALDATA

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant,reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please Contact Us.

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.